Vor Biopharma Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vor Biopharma Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($812.68M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($1.57B) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.57B) | Aug 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($32.49M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($32.49M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($32.49M) | Nov 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($27.56M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($27.84M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($27.84M) | Nov 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($30.80M) | Nov 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($30.80M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($30.80M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($33.19M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($29.98M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($29.98M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($28.43M) | May 9, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($28.43M) | Nov 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($28.43M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($23.79M) | Nov 7, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($21.66M) | Nov 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($28.11M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($274.28M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($33.29M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($28.51M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($29.04M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($32.33M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($35.32M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($32.17M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($30.42M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($24.10M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($21.79M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($22.80M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($18.60M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($18.38M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($13.73M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($11.79M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.04M) | Aug 9, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.88M) | May 6, 2021 |